Quanterix (QTRX) announced the first to market, commercial launch of two novel phospho-tau assays: p-Tau 205 and p-Tau 212, expanding its portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration. The announcement comes alongside Quanterix’s robust presence at the Alzheimer’s Association International Conference 2025, with more than 55 posters and presentations featuring data generated using its Simoa technology.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: